[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Hemerion prepares its clinical and technological development

Hemerion: a milestone

After 9 months of intense development, the Hemerion teams met on June 5 and 6 for a series of workshops to reflect on the future of the company and its technologies for cancer treatment.

In particular, Hemerion’s teams worked on the organization of the company, which has experienced strong growth over the past 12 months, with the implementation of agile Knowledge & Quality management systems and the structuring of the R&D, regulatory affairs and clinical affairs departments.

The clinical development team also explored new avenues for validating Hemerion’s therapeutic solutions for glioblastoma in France and the USA. Several topics were addressed: improving quality of life after surgery, optimizing patient management within the current standard of care, etc.

R&D teams presented several advanced projects to improve Heliance technology, notably in terms of ergonomics, ease of use and integration in the operating room, with a view to optimizing future clinical trials.

Several workshops were devoted to scientific and clinical advances in cancer treatment and their possible interactions with Hemerion technologies.

The seminar enabled Hemerion teams to share their visions and outline an ambitious roadmap for the months ahead.